BioAtla, Inc (BCAB)

Etorro trading 970x250

About BioAtla, Inc

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California. Address: 11085 Torreyana Road, San Diego, CA, United States, 92121

BioAtla, Inc News and around…

Latest news about BioAtla, Inc (BCAB) common stock and company :

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
10 Oct, 2021 FinancialContent

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed for a $100 million IPO on the Nasdaq exchange.

BioAtla, Inc. (BCAB) Fell Out Of Favor With Hedge Funds
04 Oct, 2021 Yahoo! Finance

Is BioAtla, Inc. (NASDAQ:BCAB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]

BioAtla Announces Private Placement of 2.7 Million Shares
29 Sep, 2021 Yahoo! Finance

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of institutional investors in connection with a private placement of its common stock. The Company will issue 2.7 million shares of common stock for a purchase price of $28 per share. The transaction is expected to result in gross proceeds to the Company

Oversold Conditions For BioAtla (BCAB)
20 Sep, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Add Up The Pieces: ILDR Could Be Worth $27
17 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Innovation Leaders ETF (ILDR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $26.53 per unit.

What Kind Of Shareholders Hold The Majority In BioAtla, Inc.'s (NASDAQ:BCAB) Shares?
12 Sep, 2021 Yahoo! Finance

Every investor in BioAtla, Inc. ( NASDAQ:BCAB ) should be aware of the most powerful shareholder groups. Institutions...

Implied ILDR Analyst Target Price: $26
17 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Innovation Leaders ETF (ILDR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $26.16 per unit.

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
13 Aug, 2021 Yahoo! Finance

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business.

Implied XBI Analyst Target Price: $215
12 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $214.80 per unit.

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
28 Jun, 2021 FinancialContent

Upgrades For Toll Brothers Inc (NYSE:TOL), BTIG upgraded the previous rating of Sell to Neutral. In the second quarter, ...

60 Biggest Movers From Yesterday
15 Jun, 2021 FinancialContent

Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced ...

40 Stocks Moving In Monday's Mid-Day Session
14 Jun, 2021 FinancialContent

Gainers Enochian Biosciences, Inc. (NASDAQ: ENOB) shares jumped 127.2% to $10.02. The FDA has accepted Enochian BioSciences ...

We're Hopeful That BioAtla (NASDAQ:BCAB) Will Use Its Cash Wisely
14 Jun, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysts Expect 14% Upside For VBK
09 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $321.83 per unit.

Bioatla Earns IBD Rating Upgrade
13 May, 2021 FinancialContent

Bioatla shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update
12 May, 2021 Yahoo! Finance

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update on its business.

Stock Upgrades: Bioatla Shows Rising Relative Strength
29 Apr, 2021 FinancialContent

A Relative Strength Rating upgrade for Bioatla shows improving technical performance.

IBD Rating Upgrades: Bioatla Shows Improved Price Strength
21 Apr, 2021 FinancialContent

Bioatla shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq
18 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes
17 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Who Has Been Buying BioAtla, Inc. (NASDAQ:BCAB) Shares?
16 Mar, 2021 Yahoo! Finance

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs
12 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena
11 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

16 small-cap stocks that could get a boost from ETF buying
05 Mar, 2021 FinancialContent

Several recent IPOs are due to be added to the Russell 2000 Index, according to a report from Jefferies, which could lead to buying pressure from passive ETFs that track the index.

The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
26 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
18 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
09 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

BioAtla Reaches Analyst Target Price
08 Feb, 2021 FinancialContent

In recent trading, shares of BioAtla Inc (BCAB) have crossed above the average analyst 12-month target price of $47.67, changing hands for $47.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
15 Jan, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
14 Jan, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

BioAtla, Inc (BCAB) is a NASDAQ Common Stock listed in , ,

970x250